FAM83A upregulation promotes the progression of non-small cell lung cancer (NSCLC) by inhibiting the mitogen-activated protein kinase (MAPK) signal transduction pathway (12), and promotes tumorigenicity in NSCLC via the signal-regulated kinase (ERK) pathway and phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/Akt/mTOR) pathways (18). This evidence concerns the gene WNK2 and non-small cell lung carcinoma.